A5036473530- Cannabis and Cannabinoid Research
- Homelessness and Social Issues
- Sleep and related disorders
- Hepatocellular Carcinoma Treatment and Prognosis
- Surgical Simulation and Training
- Bariatric Surgery and Outcomes
- Child and Adolescent Psychosocial and Emotional Development
- Prenatal Substance Exposure Effects
- COVID-19 and healthcare impacts
- Cardiac, Anesthesia and Surgical Outcomes
- Innovations in Medical Education
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Obesity and Health Practices
- Diet and metabolism studies
- Management of metastatic bone disease
- Anatomy and Medical Technology
- Body Contouring and Surgery
- Colorectal Cancer Screening and Detection
- Bipolar Disorder and Treatment
- Religion, Spirituality, and Psychology
- Food Security and Health in Diverse Populations
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Lung Cancer Treatments and Mutations
- Child Nutrition and Feeding Issues
- Digital Imaging in Medicine
Imperial College London
2016-2025
London Clinic
2021-2024
Downtown Women's Health Care
2023-2024
St. Mary's Hospital
2022-2023
St Mary's Hospital
2022-2023
St Mary's Hospital
2022
Phoenix Contact (United States)
2022
Institut de Virologie
2021
St Mary's Hospital
2018-2021
London Cancer
2021
Background There is a paucity of high-quality data on patient outcomes and safety after initiating treatment with cannabis-based medicinal products (CBMPs). The aim this study was to assess the clinical CBMPs by analyzing patient-reported outcome measures adverse events across broad spectrum chronic conditions.Research design methods This analyzed patients enrolled in UK Medical Cannabis Registry. Participants completed EQ-5D-5L health-related quality life, Generalized Anxiety Disorder-7...
The COVID-19 pandemic has caused global disruption to society and their health-care systems.1McKee M Stuckler D If the world fails protect economy, will damage health not just now but also in futur.Nat Med. 2020; 26: 640-642Crossref PubMed Scopus (356) Google Scholar In setting of COVID-19, organisations UK such as National Health Service (NHS) Digital, NHSX, NHS Business Services Authority have emphasised need for mobile technology managing situation. This focus led an increase phone apps...
Whilst access to cannabis-based medicinal products (CBMPs) has increased globally subject relaxation of scheduling laws globally, one the main barriers appropriate patient remains a paucity high-quality evidence surrounding their clinical effects.Whilst randomised controlled trials (RCTs) remain gold-standard for evaluation, there are notable implementation. Development CBMPs requires novel approaches collection address these challenges. Real world (RWE) presents solution not only both...
Cannabis-based medicinal products (CBMPs) are prescribed with increased frequency, despite a paucity of high-quality randomized controlled trials. The aim this study is to analyze the early outcomes first series patients CBMPs in UK respect effects on health-related quality life and clinical safety.A prospective case was performed using Medical Cannabis Registry. Primary were change patient-reported measures (EQ-5D-5L, General Anxiety Disorder-7 (GAD-7) Single-Item Sleep Quality Scale (SQS))...
Cannabis-based medicinal products (CBMPs) are prescribed with increasing frequency. This study aimed to investigate the perceived stigma attached patients CBMPs in UK establish its prevalence. A qualitative survey was developed by an expert multidisciplinary group and data were collected via Qualtrics. In total, 2319 on CBMP therapy invited take part this study. 450 (19.4%) participants completed questionnaire. 81.3% (n = 366), 76.9% 346), 61.3% 276) of reported feeling very comfortable or...
Abstract Rationale Cannabis-based medicinal products (CBMPs) have been identified as novel therapeutics for generalised anxiety disorder (GAD) based on pre-clinical models; however, there is a paucity of high-quality evidence their effectiveness and safety. Objectives This study aimed to evaluate the clinical outcomes patients with GAD treated dried flower, oil-based preparations, or combination both CBMPs. Methods A prospective cohort ( n = 302) enrolled in UK Medical Cannabis Registry...
There is growing evidence on the efficacy of cannabis-based medicinal products (CBMPs) for chronic pain (CP). Due to interaction between CP and anxiety, potential impact CBMPs both anxiety CP, this article aimed compare outcomes patients with without co-morbid following CBMP treatment.Participants were prospectively enrolled categorized by baseline General Anxiety Disorder-7(GAD-7) scores, into 'no anxiety'(GAD-7 < 5) 'anxiety'(GAD-7 ≥ cohorts. Primary changes in Brief Pain Inventory...
Background The following study evaluated the clinical outcomes of patients enrolled in UK Medical Cannabis Registry, who were treated with inhaled dried flower (Adven® EMT2, Curaleaf International, Guernsey), and sublingual/oral medium-chain triglyceride-based oils (Adven, Guernsey) for chronic pain.Methods In this cohort study, primary changes validated patient reported outcome measures (PROMs) at 1, 3, 6 months compared to baseline, adverse event analysis. Statistical significance was...
The UK Medical Cannabis Registry is the largest real world data platform for medical cannabis outcomes in UK, providing insight into clinical and monitoring safety of this novel therapy. This study aims to assess functionality accessibility online collection patient priorities future research. Descriptive statistics were used analyze quantitative data. For open-ended questions an inductive thematic analysis was performed. 600 responses recorded. 554 (92.3%) patients had platform. 272 (90.4%)...
There is a paucity of research, especially in the UK, that investigates individual differences both medical and recreational cannabis users. A cross-sectional survey study design was used to assess users currently living UK. Recreational were invited take part via social media. Medical recruited from Sapphire Clinics, London, which provides treatment with prescribed cannabis-based medicinal products. Demographic data use frequency, as well post-traumatic stress disorder symptoms (PCL-5),...
To explore pain-specific, general health-related quality of life (HRQoL), and safety outcomes chronic pain patients prescribed cannabis-based medicinal products (CBMPs).A case series was performed using with from the UK Medical Cannabis Registry. Primary were changes in Brief Pain Inventory short-form (BPI), Short-form McGill Questionnaire-2 (SF-MPQ-2), Visual Analogue Scale-Pain (VAS), General Anxiety Disorder-7 (GAD-7), Sleep Quality Scale (SQS), EQ-5D-5L, at 1, 3, 6 months baseline....
Introduction: There is a growing body of literature supporting the efficacy cannabis-based medicinal products (CBMPs). Despite an increase in prescribing globally, there paucity high-quality clinical data on CBMPs for many conditions. This study aims to detail changes health-related quality life (HRQoL) and associated safety patients prescribed any indication from UK Medical Cannabis Registry (UKMCR). Methods: An uncontrolled prospective case series UKMCR was analyzed. Primary outcomes...
Background Although pre-clinical experiments associate cannabinoids with reduced depressive symptoms, there is a paucity of clinical evidence. This study aimed to analyze the health-related quality life changes and safety outcomes in patients prescribed cannabis-based medicinal products (CBMPs) for depression.Methods An uncontrolled case series UK Medical Cannabis Registry was analyzed. Primary were from baseline Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7),...
Cancer pain (CP) is a prevalent condition with limited pharmacotherapeutic options. Cannabis-based medicinal products (CBMPs) have shown analgesic effects, but their efficacy in CP remains contentious. This study aims to evaluate the change patient-reported outcome measures (PROMs) and adverse events (AEs) patients treated CBMPs. A case series was conducted using prospectively collected clinical data from UK Medical Cannabis Registry. Primary outcomes were changes Brief Pain Inventory (BPI),...
Objective The study aims to evaluate the clinical outcomes in patients with hypermobility spectrum disorder (HSD) and hypermobile Ehlers–Danlos syndrome (hEDS) chronic pain following treatment cannabis‐based medicinal products (CBMPs). Methods This was a case series conducted UK Medical Cannabis Registry. primary were changes validated patient‐reported outcome measures at 1, 3, 6, 12, 18 months compared baseline: Short‐Form McGill Pain Questionnaire 2 (SF‐MPQ‐2), visual analog scale score...
The increasing global consumption of cannabis, particularly within unregulated markets, raises concerns about potential health risks associated with contaminants and adulterants. This study investigates the presence active compounds adulterants in illicit cannabis products UK. Data was identified from 1,635 samples submitted to Welsh Emerging Drugs & Identification Novel Substances (WEDINOS). Of these, 695 (42.51%) did not contain any naturally occurring cannabinoids 162 (9.91%) no compound...
Cannabis-based medicinal products (CBMPs) are an emerging therapeutic option in the management of primary chronic pain, using role endocannabinoid system modulating central and peripheral pain processes. Despite promising preclinical data, there is a paucity high-quality evidence to support use CBMPs for pain. This study aimed investigate health-related quality-of-life outcomes patients with who were prescribed CBMP oil preparations (Adven, Curaleaf International, Guernsey, UK). case series...
Anxiety disorders are one of the most common reasons for seeking treatment with cannabis-based medicinal products (CBMPs). Current pharmacological treatments variable in efficacy and endocannabinoid system has been identified as a potential therapeutic target. This study aims to detail changes health-related quality-of-life (HRQoL) clinical safety following CBMP therapy generalized anxiety disorder.A case series from UK Medical Cannabis Registry was performed. Primary outcomes included...